Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)

Sponsor
Chinese PLA General Hospital
Study ID
NCT02596256
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
  • Docetaxel — DRUG
    Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity

Study Details

Apatinib plus docetaxel versus docetaxel as second-line treatment in advanced gastric cancer.

Key Dates

Start date
Apr 30, 2016
Status verified
Apr 2018
Primary completion
Feb 28, 2019
Completion
Feb 28, 2019

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: control group
    Apatinib Mesylate Tablets (500 mg qd p.o.) and Docetaxel (60mg/m2 i.v. d1 q21d)
  • Active Comparator: contrast group
    Docetaxel (60mg/m2, i.v. d1 q21d)

Primary Outcome Measure

Progression free survival [ Time Frame: 6 months ]

Related Studies